HaemaLogiX announces issuance of South Korean patent for KMA.CAR-T

HaemaLogiX’s South Korean patent 'Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof' was granted in South Korea on 5 January 2024.

The patent covers compositions and methods for treating KMA-expressing malignancies, including chimeric antigen receptors (CARs) and T cells containing CARs (CAR-T cells). The patent also covers methods and compositions comprising CAR-T cells co-expressing other anti-tumoral agents including cytokines and antibodies.

This patent has also been granted in Australia, USA, China, Russia, Israel and Japan and is under review in other jurisdictions.